THMO vs. KEQU, AIKI, IBIO, PPBT, SYBX, VBIV, TCRT, KALA, PMCB, and APTO
Should you be buying ThermoGenesis stock or one of its competitors? The main competitors of ThermoGenesis include Kewaunee Scientific (KEQU), AIkido Pharma (AIKI), iBio (IBIO), Purple Biotech (PPBT), Synlogic (SYBX), VBI Vaccines (VBIV), Alaunos Therapeutics (TCRT), KALA BIO (KALA), PharmaCyte Biotech (PMCB), and Aptose Biosciences (APTO).
ThermoGenesis (NASDAQ:THMO) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, ThermoGenesis and ThermoGenesis both had 3 articles in the media. ThermoGenesis' average media sentiment score of 1.59 beat Kewaunee Scientific's score of 1.29 indicating that ThermoGenesis is being referred to more favorably in the media.
Kewaunee Scientific has a net margin of 4.34% compared to ThermoGenesis' net margin of -153.43%. Kewaunee Scientific's return on equity of 20.82% beat ThermoGenesis' return on equity.
Kewaunee Scientific has higher revenue and earnings than ThermoGenesis.
Kewaunee Scientific received 109 more outperform votes than ThermoGenesis when rated by MarketBeat users. Likewise, 68.18% of users gave Kewaunee Scientific an outperform vote while only 60.47% of users gave ThermoGenesis an outperform vote.
ThermoGenesis currently has a consensus target price of $5.00, suggesting a potential upside of 777.96%. Given ThermoGenesis' higher probable upside, research analysts clearly believe ThermoGenesis is more favorable than Kewaunee Scientific.
ThermoGenesis has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Comparatively, Kewaunee Scientific has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by insiders. Comparatively, 14.5% of Kewaunee Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Kewaunee Scientific beats ThermoGenesis on 9 of the 14 factors compared between the two stocks.
Get ThermoGenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for THMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ThermoGenesis Competitors List
Related Companies and Tools
